

June 08, 2024

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001
BSE Scrip Code: 543427

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex
Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS

Dear Sir/Madam,

Sub: Intimation under Regulation 30 read with Schedule III of SEBI (LODR) Regulations, 2015 (“SEBI Listing Regulations”)

Pursuant to Regulation 30 of SEBI Listing Regulations, we would like to inform that one of the subsidiary Company i.e., Optival Health Solutions Private Limited has received four suspension orders of License/operations for stores situated at various locations in Karnataka. Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 details is given below:

Name(s) of the Authority	Nature and details of the action(s) taken, initiated or order(s) passed	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Details of the violation(s)/ contravention(s) committed or alleged to be committed	Impact on financial operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible
Assistant Director, Drugs Control Administration, Bangalore Circle-06 Karnataka	Suspension of Drug License for two days and one day of stores situated at Shantipura and Hebbagodi, Karnataka respectively.	Order received on 07.06.2024	Rule 65(2), 65(4)(4)(i), 65(3)(1), 65(3)(1)(h), 65(4)(4)(i), 65(3)(1), 65 (6) under Drugs & Cosmetics Act, 1940 and Rules, 1945	Potential Revenue Loss of Rs~ 1.71 Lacs and Rs~ 0.30 Lacs respectively.
Assistant Director, Drugs Control Administration, Bangalore Circle-05 Karnataka	Suspension of Drug License for three days and one day of stores situated at Kothanoor and Kanaka Nagar, Karnataka respectively.	Order received on 07.06.2024	Rule 65(2), 65 (4)(3)(ii), 65(3)(1)(c) , 65 (3)(1)(d), 65 (3)(1)(g), 65 (4)(3)(ii), 65 (4)(4)(i), 65(6), 65(3)(1)(h) under Drugs & Cosmetics Act, 1940 and Rules, 1945	Potential Revenue Loss of Rs~ 3.65 Lacs and Rs~ 0.56 Lacs respectively.

Kindly take the same on records.

For MedPlus Health Services Limited

Manoj Kumar Srivastava
Company Secretary
FCS 7460

 040-6724 672